HER2-ultralow classification allows identification of patients with very low HER2 expression, offering personalized treatment options for previously underserved groups. DESTINY-Breast06 trial ...

A new analysis of data from the KeyNote-042 trial in previously-untreated NSCLC has shown that the drug is effective regardless of whether a patient’s tumour bears KRAS mutations – which make ...

Some tumors also carry a common genetic change called a PIK3CA mutation ... HER2-low breast cancer does not represent a distinct biologic and prognostic subtype, the introduction of HER2-low ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...